Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
P/B ratio for Lipella Pharmaceuticals Inc. (LIPO)
P/B ratio as of 2023: 15.58
According to Lipella Pharmaceuticals Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 15.58. At the end of 2022 the company had a P/B ratio of 30.76.
P/B ratio history for Lipella Pharmaceuticals Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 15.58 |
| 2022 | 30.76 |
| 2021 | 23.20 |
| 2020 | 70.66 |
| 2019 | -276.62 |